How Analysts Feel About Bioptix Inc (BIOP) After Today’s Huge Increase?

September 17, 2017 - By Darrin Black

The stock of Bioptix Inc (NASDAQ:BIOP) is a huge mover today! The stock increased 4.17% or $0.17 on September 15, reaching $4.25. About 50,425 shares traded or 297.49% up from the average. Bioptix Inc (NASDAQ:BIOP) has declined 8.56% since September 17, 2016 and is downtrending. It has underperformed by 25.26% the S&P500.
The move comes after 6 months positive chart setup for the $22.97 million company. It was reported on Sep, 17 by We have $4.59 PT which if reached, will make NASDAQ:BIOP worth $1.84M more.

More notable recent Bioptix Inc (NASDAQ:BIOP) news were published by: which released: “4.25” on September 23, 2016, also with their article: “Bioptix Announces Streamlining of Workforce” published on January 20, 2017, published: “Bioptix, Inc. Holds Special Shareholder Meeting” on August 23, 2017. More interesting news about Bioptix Inc (NASDAQ:BIOP) were released by: and their article: “Bioptix Announces Executive Leadership Change” published on April 10, 2017 as well as‘s news article titled: “Venaxis Reports Name Change to Bioptix, Inc and NASDAQ Ticker Symbol Change to …” with publication date: December 08, 2016.

Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance platform for the detection of molecular interactions. The company has market cap of $22.97 million. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. It currently has negative earnings. The Company’s SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: